专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110318304A1 DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR 审中-公开
标题翻译：检测EPHA3作为固体肿瘤存在的标记
公开(公告)号：US20110318304A1
公开(公告)日：2011-12-29
申请号：US13164581
申请日：2011-06-20
申请人： Martin Lackmann , Andrew Mark Scott , Catherine To , Christopher R. Bebbington , Geoffrey T. Yarranton , Mark Baer , Varghese Palath
发明人： Martin Lackmann , Andrew Mark Scott , Catherine To , Christopher R. Bebbington , Geoffrey T. Yarranton , Mark Baer , Varghese Palath
IPC分类号： A61K38/20 , G01N33/574 , A61P35/00 , A61K39/395 , A61K38/21 , C12Q1/48 , C12Q1/68
CPC分类号： C07K16/2866 , G01N33/57492 , G01N2333/70585 , G01N2333/70589 , G01N2800/52
摘要： The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
摘要翻译：本发明提供用于检测癌症患者中非造血，非肿瘤EphA3表达细胞的方法和组合物，并用于监测使用EphA3的患者的预后。

2. 发明授权

US08637016B2 EphA3 antibodies for the treatment of solid tumors 有权
标题翻译： EphA3抗体用于治疗实体瘤
公开(公告)号：US08637016B2
公开(公告)日：2014-01-28
申请号：US12045589
申请日：2008-03-10
申请人： Martin Lackmann , Andrew Mark Scott , Christopher R. Bebbington , Geoffrey T. Yarranton , Carmelina Murone , Catherine To
发明人： Martin Lackmann , Andrew Mark Scott , Christopher R. Bebbington , Geoffrey T. Yarranton , Carmelina Murone , Catherine To
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6849 , A61K51/1033 , A61K2039/505 , C07K2317/24 , C07K2317/73
摘要： The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
摘要翻译：本发明提供包含用于治疗实体瘤的抗EphA3抗体的方法和组合物。

3. 发明申请

US20080286272A1 EphA3 Antibodies for the Treatment of Solid Tumors 有权
标题翻译： EphA3治疗实体肿瘤的抗体
公开(公告)号：US20080286272A1
公开(公告)日：2008-11-20
申请号：US12045589
申请日：2008-03-10
申请人： Martin Lackmann , Andrew Mark Scott , Christopher R. Bebbington , Geoffrey T. Yarranton , Carmelina Murone , Catherine To
发明人： Martin Lackmann , Andrew Mark Scott , Christopher R. Bebbington , Geoffrey T. Yarranton , Carmelina Murone , Catherine To
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6849 , A61K51/1033 , A61K2039/505 , C07K2317/24 , C07K2317/73
摘要： The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.
摘要翻译：本发明提供包含用于治疗实体瘤的抗EphA3抗体的方法和组合物。

4. 发明授权

US5731166A Recombinant production of chemotactic CP-10 polypeptides and therapeutic methods using them 失效
标题翻译：重组产生趋化性CP-10多肽和使用它们的治疗方法
公开(公告)号：US5731166A
公开(公告)日：1998-03-24
申请号：US987272
申请日：1993-04-23
申请人： Carolyn Geczy , Richard John Simpson , Martin Lackmann
发明人： Carolyn Geczy , Richard John Simpson , Martin Lackmann
IPC分类号： A61K38/00 , C07K14/52 , C07K16/24 , C12N15/12 , C12P21/08 , C12N15/19
CPC分类号： C07K16/24 , C07K14/52 , A61K38/00
摘要： The chemotactic protein CP-10, in essentially pure form, having an apparent molecular weight of approximately 10 kD and having chemotactic activity for neutrophils, monocytes/macrophages and/or other mammalian cells, or an analogue, mutant, fragment, derivative or functional homologue of CP-10. Amino acid and nucleotide sequences for CP-10 are disclosed, as well as production and use thereof.
摘要翻译： PCT No.PCT / AU91 / 00410 Sec。 371日期：1993年4月23日 102（e）日期1993年4月23日PCT 1991年9月5日PCT公布。第WO92 / 04376号公报日期1992年3月19日基本上纯的形式的趋化蛋白CP-10具有约10kD的表观分子量并且对嗜中性粒细胞，单核细胞/巨噬细胞和/或其它哺乳动物细胞具有趋化活性，或类似物，突变体片段，CP-10的衍生或功能同系物。公开了CP-10的氨基酸和核苷酸序列，以及其生产和使用。

5. 发明申请

US20080317763A1 Regulation of Metalloprotease Cleavage of Cell Surface Proteins 有权
标题翻译：金属蛋白酶切割细胞表面蛋白的调控
公开(公告)号：US20080317763A1
公开(公告)日：2008-12-25
申请号：US11721949
申请日：2005-12-19
申请人： Martin Lackmann , Peter W. Janes , Dimitar B. Nikolov , Nayanendu Saha
发明人： Martin Lackmann , Peter W. Janes , Dimitar B. Nikolov , Nayanendu Saha
IPC分类号： A61K39/395 , C12N9/50 , C12N15/11 , C12N15/00 , C12N5/06 , A61P43/00 , C07K16/18 , C12Q1/37 , A61K38/43
CPC分类号： A61K38/57 , C12N9/6489
摘要： Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates. These inhibitors will be useful in therapeutic intervention of tumour development, invasion and metastasis and other diseases which involve the activity of the ADAM10 and ADAM17 proteases, such as inflammation, cardio-vascular disease, arthritis and other auto-immune diseases.
摘要翻译：阐明ADAM10底物识别和蛋白酶定位模块的晶体结构，其包含富含蛋白质的富含蛋白酶和去整合素结构域，以及详细的功能分析表明，富含半胱氨酸的结构域内的酸性口袋形成底物识别位点。该口袋与受体/配体复合物的结合有助于有效的配体切割，这在口袋中的关键残基改变时被阻止。这提供了ADAM10细胞外结构域中的表面袋的使用以及相关蛋白酶如ADAM17中相应的结构，作为用于小分子底物特异性抑制剂或单克隆抗体的基于结构的计算和高通量筛选的靶标抑制ephrins和其他ADAM10或ADAM17底物的ADAM蛋白酶切割。这些抑制剂可用于涉及ADAM10和ADAM17蛋白酶如炎症，心血管疾病，关节炎和其他自身免疫疾病的活动的肿瘤发展，侵袭和转移以及其他疾病的治疗性干预。

6. 发明授权

US07037662B1 Receptor-ligand system and assay 失效
标题翻译：受体 - 配体系统和测定
公开(公告)号：US07037662B1
公开(公告)日：2006-05-02
申请号：US09104340
申请日：1998-06-25
申请人： Andrew Wallace Boyd , Mirella Dottori , Martin Lackmann
发明人： Andrew Wallace Boyd , Mirella Dottori , Martin Lackmann
IPC分类号： G01N33/50 , C07K14/00 , C12N15/00 , C07H21/04
CPC分类号： C12N9/1205 , C07K14/715 , G01N33/566
摘要： An Eph family RTK (receptor tyrosine kinase) ligand-binding domain as well as a method of identifying Eph family RTK agonists or antagonist. The ligand-binding domain is suitably encoded by exon III of a gone encoding the RTK of the Eph family and may additionally include an amino acid sequence encoded by exon II of the gene. The ligand-binding domain may be a polypeptide having amino acids 57-271 of the sequence shown in FIG. 1.
摘要翻译： Eph家族RTK（受体酪氨酸激酶）配体结合域以及鉴定Eph家族RTK激动剂或拮抗剂的方法。配体结合结构域适当地由编码Eph家族的RTK的外显子III编码，并且还可以包括由该基因的外显子II编码的氨基酸序列。配体结合结构域可以是具有图1所示序列的第57-271位氨基酸的多肽。 1。

7. 发明授权

US07960513B2 Antibody against a human ADAM protease 有权
标题翻译：针对人ADAM蛋白酶的抗体
公开(公告)号：US07960513B2
公开(公告)日：2011-06-14
申请号：US11721949
申请日：2005-12-19
申请人： Martin Lackmann , Peter W. Janes , Dimitar B. Nikolov , Nayanendu Saha
发明人： Martin Lackmann , Peter W. Janes , Dimitar B. Nikolov , Nayanendu Saha
IPC分类号： C07K16/40
CPC分类号： A61K38/57 , C12N9/6489
摘要： Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates. These inhibitors will be useful in therapeutic intervention of tumour development, invasion and metastasis and other diseases which involve the activity of the ADAM10 and ADAM17 proteases, such as inflammation, cardio-vascular disease, arthritis and other auto-immune diseases.
摘要翻译：阐明ADAM10底物识别和蛋白酶定位模块的晶体结构，其包含富含蛋白质的富含蛋白酶和去整合素结构域，以及详细的功能分析表明，富含半胱氨酸的结构域内的酸性口袋形成底物识别位点。该口袋与受体/配体复合物的结合有助于有效的配体切割，这在口袋中的关键残基改变时被阻止。这提供了ADAM10细胞外结构域中的表面袋的使用以及相关蛋白酶如ADAM17中相应的结构，作为用于小分子底物特异性抑制剂或单克隆抗体的基于结构的计算和高通量筛选的靶标抑制ephrins和其他ADAM10或ADAM17底物的ADAM蛋白酶切割。这些抑制剂可用于涉及ADAM10和ADAM17蛋白酶如炎症，心血管疾病，关节炎和其他自身免疫疾病的活动的肿瘤发展，侵袭和转移以及其他疾病的治疗性干预。

8. 发明申请

US20060140957A1 Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis 审中-公开
标题翻译： Eph / ephrin介导的细胞粘附和肿瘤细胞转移的调节
公开(公告)号：US20060140957A1
公开(公告)日：2006-06-29
申请号：US10544701
申请日：2004-02-09
申请人： Martin Lackmann , Sabine Wimmer-Kleikamp , Andrew Scott , Christopher Vearing , Andrew Boyd
发明人： Martin Lackmann , Sabine Wimmer-Kleikamp , Andrew Scott , Christopher Vearing , Andrew Boyd
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： A61K47/64 , C07K2319/30
摘要： Methods and compositions for modulating ephrin/Eph receptor-mediated cell adhesion and/or cell repulsion are provided, particularly in relation to preventing, inhibiting or delaying tumour cell metastasis through modulation of Eph receptor-ephrin binding interactions and subsequent Eph receptor signalling. Particular agents useful according to the invention are agents which interfere with a ephrin-Eph receptor binding such as soluble ephrins and Eph receptors and antibodies directed to ephrins and Eph receptors, ephrin-cytotoxic drug conjugates which kill tumour cells, metalloprotease inhibitors and inhibitors of protein tyrosine phosphatase activity.
摘要翻译：提供了用于调节ephrin / Eph受体介导的细胞粘附和/或细胞排斥的方法和组合物，特别是关于通过调节Eph受体-ephrin结合相互作用和随后的Eph受体信号传导来预防，抑制或延迟肿瘤细胞转移。根据本发明有用的特定试剂是干扰ephrin-Eph受体结合的试剂，例如可溶性ephrins和Eph受体和针对ephrins和Eph受体的抗体，杀死肿瘤细胞的ephrin-细胞毒性药物偶联物，金属蛋白酶抑制剂和蛋白质抑制剂酪氨酸磷酸酶活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式